{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:26:29Z","timestamp":1783088789896,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the acute setting, PTH-independent hypercalcemia is typically treated with anti-resorptive agents such as zoledronic acid or denosumab. When these agents are no longer able to control hypercalcemia, several case reports have shown the utility of cinacalcet. However, it is not known if cinacalcet can be effective in patients na\u00efve to anti-resorptive therapy or how cinacalcet ameliorates the hypercalcemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 47-year-old male with a history of alcohol-induced cirrhosis was admitted for left cheek bleeding and swelling from an infiltrative squamous cell carcinoma of the oral cavity. On admission, he was found to have an elevated albumin-corrected serum calcium of 13.6\u00a0mg\/dL, a serum phosphorus of 2.2\u00a0mg\/dL and an intact PTH of 6 pg\/mL (normal 18\u201390) with a PTHrP of 8.1 pmol\/L (normal\u2009&lt;\u20094.3), consistent with PTHrP-dependent hypercalcemia. Aggressive intravenous saline hydration and subcutaneous salmon calcitonin were initiated, but his serum calcium remained elevated. Given tooth extractions scheduled for the next day and possible irradiation to the jaw in the near future, alternatives to antiresorptive therapy were sought. Cinacalcet was initiated at 30\u00a0mg twice daily then increased to 60\u00a0mg twice daily the following day. The albumin-corrected serum calcium level decreased from 13.2 to 10.9\u00a0mg\/dL within 48\u00a0h. The fractional excretion of calcium increased from 3.7 to 7.0%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case demonstrates the utility of cinacalcet for the treatment of PTHrP-mediated hypercalcemia without prior anti-resorptive therapy via increased renal clearance of calcium.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-023-01386-3","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:03:47Z","timestamp":1686895427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Samya","family":"Faiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lavelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Shoback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-4225","authenticated-orcid":false,"given":"Gregory","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558\u201367.","journal-title":"J Clin Oncol"},{"key":"1386_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1078155213518361","volume":"21","author":"A Dietzek","year":"2015","unstructured":"Dietzek A, Connelly K, Cotugno M, Bartel S, McDonnell AM. Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract. 2015;21:143\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"DM Shoback","year":"2003","unstructured":"Shoback DM, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:5644\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/ndt\/gfh924","volume":"20","author":"AE Kruse","year":"2005","unstructured":"Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1311\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jbmr.3864","volume":"35","author":"Z Cheng","year":"2020","unstructured":"Cheng Z, et al. Calcium-sensing receptors in chondrocytes and osteoblasts are required for Callus Maturation and Fracture Healing in mice. J Bone Miner Res. 2020;35:143\u201354.","journal-title":"J Bone Miner Res"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199711203372104","volume":"337","author":"SJ Silverberg","year":"1997","unstructured":"Silverberg SJ, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med. 1997;337:1506\u201310.","journal-title":"N Engl J Med"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000335676","volume":"5","author":"A Bech","year":"2012","unstructured":"Bech A, Smolders K, Telting D, de Boer H. Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related peptide. Case Rep Oncol. 2012;5:1\u20138.","journal-title":"Case Rep Oncol"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1593\/neo.101620","volume":"13","author":"G Lorch","year":"2011","unstructured":"Lorch G, et al. The calcium-sensing receptor is necessary for the rapid development of hypercalcemia in human lung squamous cell carcinoma. Neoplasia. 2011;13:428\u201338.","journal-title":"Neoplasia"},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1006\/bbrc.2000.2157","volume":"269","author":"JL Sanders","year":"2000","unstructured":"Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM. Extracellular calcium-sensing receptor (CaR) expression and its potential role in parathyroid hormone-related peptide (PTHrP) secretion in the H-500 rat leydig cell model of humoral hypercalcemia of malignancy. Biochem Biophys Res Commun. 2000;269:427\u201332.","journal-title":"Biochem Biophys Res Commun"},{"key":"1386_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000506100","volume":"13","author":"M Sheehan","year":"2020","unstructured":"Sheehan M, Tanimu S, Tanimu Y, Engel J, Onitilo A. Cinacalcet for the treatment of Humoral Hypercalcemia of Malignancy: an introductory case report with a pathophysiologic and therapeutic review. Case Rep Oncol. 2020;13:321\u20139.","journal-title":"Case Rep Oncol"},{"key":"1386_CR11","first-page":"1779","volume":"11","author":"H Sternlicht","year":"2015","unstructured":"Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015;11:1779\u201388.","journal-title":"Ther Clin Risk Manag"},{"key":"1386_CR12","doi-asserted-by":"crossref","unstructured":"Asonitis N, et al. Hypercalcemia of malignancy treated with cinacalcet. Endocrinol Diabetes Metab Case Rep. 2017;17\u20130118.","DOI":"10.1530\/EDM-17-0118"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1590\/2359-3997000000291","volume":"61","author":"H Valdes-Socin","year":"2017","unstructured":"Valdes-Socin H, et al. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor. Arch Endocrinol Metab. 2017;61:506\u20139.","journal-title":"Arch Endocrinol Metab"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"110149","DOI":"10.1016\/j.mehy.2020.110149","volume":"143","author":"MT Sheehan","year":"2020","unstructured":"Sheehan MT, Wermers RA, Jatoi A, Loprinzi CL, Onitilo AA. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy. Med Hypotheses. 2020;143:110149.","journal-title":"Med Hypotheses"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-20-0487","volume":"10","author":"S O\u2019Callaghan","year":"2021","unstructured":"O\u2019Callaghan S, Yau H. Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift. Endocr Connect. 2021;10:R13\u2013R24.","journal-title":"Endocr Connect"},{"key":"1386_CR16","doi-asserted-by":"crossref","unstructured":"Christensen BR, Rendo MJ, Beeler BW, Huddleston BJ, Fenderson JL. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein. Cureus. 2022;14:e23398.","DOI":"10.7759\/cureus.23398"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00240-018-1096-0","volume":"47","author":"G Vezzoli","year":"2019","unstructured":"Vezzoli G, Macrina L, Magni G, Arcidiacono T. Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis. Urolithiasis. 2019;47:23\u201333.","journal-title":"Urolithiasis"},{"key":"1386_CR18","doi-asserted-by":"crossref","unstructured":"Lee JJ, et al. Activation of the calcium sensing receptor attenuates TRPV6-dependent intestinal calcium absorption. JCI Insight. 2019;5:e128013.","DOI":"10.1172\/jci.insight.128013"},{"key":"1386_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48:303\u201311.","journal-title":"Clin Pharmacokinet"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01386-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01386-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01386-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:04:02Z","timestamp":1686895442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01386-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01386-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Signed informed consent was obtained directly from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Signed informed consent to publish this case report was obtained directly from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}